 |
|
A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy
Sang Youb Han, Chan-Young Jung, Sang Ho Lee, Dong Won Lee, Sik Lee, Chan-Duck Kim, Bum Soon Choi, Beom Seok Kim
Kidney Res Clin Pract. 2022;41(4):452-461. Published online 2022 May 4 DOI: https://doi.org/10.23876/j.krcp.21.146
|
|
Citations to this article as recorded by
 Mycophenolate Mofetil and Steroid for Treatment of Patients With IgA Nephropathy
Jing Miao, Parikshit Duriseti, Yeshwanter Radhakrishnan, Lisa Vaughan, Fernando C. Fervenza, Ladan Zand
Kidney International Reports.2024; 9(1): 182. CrossRef New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023?
Bryce Barr, Sean Barbour
Current Opinion in Nephrology & Hypertension.2024; 33(3): 311. CrossRef Efficacy and safety of biologic agents for IgA nephropathy: A protocol for systematic review and meta-analysis
Jia Ma, Jianyue Xing, Yupeng Zhang, Guangzhen Liu, Rajendra Bhimma
PLOS ONE.2024; 19(3): e0298732. CrossRef Exosome-Based Drug Delivery: Translation from Bench to Clinic
Hee Byung Koh, Hyo Jeong Kim, Shin-Wook Kang, Tae-Hyun Yoo
Pharmaceutics.2023; 15(8): 2042. CrossRef
|